NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»01/09/2009 [Industry news]
Sinovac: H1N1 vaccine passes SFDA experts evaluation

Sinovac Biotech, a leading provider of biopharmaceutical products in China, has announced that its H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA), China.

 
Sinovac Biotech, a leading provider of biopharmaceutical products in China, has announced that its H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA), China. The vaccine is expected to obtain the production license within this week. According to the company, on August 30 and 31, 2009, SFDA organized and held an experts evaluation conference focused on A/H1N1 vaccines to evaluate Sinovac\'s H1N1 vaccine, which recently completed all clinical trials. Top-line results from the trial demonstrated Sinovac\'s H1N1 vaccine to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot. No severe adverse events were reported after inoculation. Based on the results of the evaluation, the experts unanimously agreed that Sinovac\'s H1N1 vaccine is applicable to all people from 3 to 60 years old and the vaccination schedule is single shot. The result of the experts evaluation conference will be submitted to SFDA on September 1st, which will be the primary opinion for SFDA to issue the production license. Sinovac submitted the H1N1 split influenza vaccine without adjuvant for registration approval, which is applicable to all people from 3 to 60 years old. The dosage is 15ug/0.5ml/dose. Only one shot is needed for inoculation. Mr Weidong Yin, Chairman, Sinovac said, \"We are very excited to see that our H1N1 vaccine has passed the experts evaluation conference organized by SFDA. The evaluation result will be the important opinion for SFDA to issue the production license. We expect to obtain the production license within one week. With this approval, we can continue to fulfill our mission to provide top-quality vaccines to prevent and control the spreading of H1N1 virus not only in China, but worldwide.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.